A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/02/2006	CA2609342A1 Nucleoside compounds and methods of use thereof
11/02/2006	CA2608111A1 Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
11/02/2006	CA2607434A1 Use of a clobetasol spray formulation to treat psoriasis
11/02/2006	CA2607426A1 Fused thiazole derivatives as kinase inhibitors
11/02/2006	CA2607391A1 Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
11/02/2006	CA2606947A1 Methods and compositions for treating pain
11/02/2006	CA2606517A1 Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof
11/02/2006	CA2606473A1 Benzisoxazole piperazine compounds and methods of use thereof
11/02/2006	CA2606471A1 Benzisoxazole piperidine compounds and methods of use thereof
11/02/2006	CA2606399A1 Use of compounds to enhance processivity of telomerase
11/02/2006	CA2606251A1 Imidazo(1,2-a)pyridine derivatives useful as peptide deformylase (pdf) inhibitors
11/02/2006	CA2606239A1 Preventive or remedy for bowel disease
11/02/2006	CA2606226A1 Materials and methods for enhanced degradation of mutant proteins associated with human disease
11/02/2006	CA2606093A1 Water-soluble films comprising nicotine
11/02/2006	CA2606087A1 Novel oxadiazole derivatives and their medical use
11/02/2006	CA2606086A1 Trpv1 agonist compounds and methods for making and using the same
11/02/2006	CA2606077A1 Polymorphic and amorphous salt forms of squalamine dilactate
11/02/2006	CA2606064A1 Methods for modulating bladder function
11/02/2006	CA2606053A1 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
11/02/2006	CA2606025A1 Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
11/02/2006	CA2606011A1 Pro-drugs of n-thiazol-2yl-benzamide derivatives
11/02/2006	CA2605926A1 Opioid receptor agonist compounds and their use in treatment of pain
11/02/2006	CA2605925A1 Imidazo [1, 2-a] pyridine derivatives useful as peptide deformylase (pdf) inhibitors
11/02/2006	CA2605918A1 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
11/02/2006	CA2605815A1 Low-calcemic 16,23-diene 25-oxime analogs of 1alpha,25-dihydroxy vitamin d3
11/02/2006	CA2605796A1 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
11/02/2006	CA2605792A1 Extended release formulations
11/02/2006	CA2605783A1 Matrix metalloproteinase inhibitors of tgf .beta.-induced subcapsular cataract formation
11/02/2006	CA2605771A1 Methods of treating atherosclerosis
11/02/2006	CA2605756A1 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
11/02/2006	CA2605748A1 Novel specific caspase-10 inhibitors
11/02/2006	CA2605744A1 Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
11/02/2006	CA2605674A1 Sustained release formulation and dosing schedules of leukotriene synthesis inhibitor for human therapy
11/02/2006	CA2605669A1 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes
11/02/2006	CA2605603A1 Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
11/02/2006	CA2605594A1 Heterocyclic compound
11/02/2006	CA2605587A1 Chromane and chromene derivatives and uses thereof
11/02/2006	CA2605580A1 Benzodioxane and benzodioxolane derivatives and uses thereof
11/02/2006	CA2605554A1 Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
11/02/2006	CA2605480A1 Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls
11/02/2006	CA2605447A1 Therapeutic combinations for the treatment or prevention of psychotic disorders
11/02/2006	CA2605435A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	CA2605383A1 Phthalazinone derivative and pharmaceutical comprising the same
11/02/2006	CA2605381A1 Crystal polymorphism of 4'-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3',5'-dimethylbiphenylcarboxylic acid hydrochloride
11/02/2006	CA2605365A1 Remedy for xanthoma
11/02/2006	CA2605351A1 N-substituted phenylacetamide derivative and pharmaceutical composition comprising the same
11/02/2006	CA2605331A1 Calcium bis[(2s)-3-[3-[(2s)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy]phenyl]-2-isopropoxypropionate] and intermediate thereof
11/02/2006	CA2605306A1 Therapeutic agent for keratoconjunctival disorder
11/02/2006	CA2605302A1 Combined pharmaceutical preparation for treatment of type 2 diabetes
11/02/2006	CA2605275A1 Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
11/02/2006	CA2605267A1 Acetylene derivatives
11/02/2006	CA2605265A1 Acetylene derivatives
11/02/2006	CA2605117A1 Treatment of pain
11/02/2006	CA2605110A1 Benzothiophene derivatives
11/02/2006	CA2605069A1 Treatment of drug abuse
11/02/2006	CA2604916A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	CA2604915A1 New therapeutic combinations for the treatment or prevention of depression
11/02/2006	CA2604759A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	CA2604603A1 Novel cyclic amines
11/02/2006	CA2604531A1 Vla-4 antagonists
11/02/2006	CA2604518A1 Phenyl ethyne compounds
11/02/2006	CA2604454A1 Artificial cerebrospinal fluid
11/02/2006	CA2604383A1 Nutrition with lipids and non-digestible saccharides
11/02/2006	CA2604284A1 Protein kinase inhibitors
11/02/2006	CA2604225A1 Surface-modified microparticles and methods of forming and using the same
11/02/2006	CA2604190A1 Angiotensin ii receptor antagonists
11/02/2006	CA2603986A1 Benzothiophene hydroxamic acid derivatives
11/02/2006	CA2603947A1 Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
11/02/2006	CA2603900A1 Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
11/02/2006	CA2603807A1 Polymorph form ii of tanaproget
11/02/2006	CA2603786A1 Purified form of tanaproget
11/02/2006	CA2603594A1 Micronized tanaproget and compositions containing same
11/02/2006	CA2602368A1 Use of novel compounds for ibd treatment
11/02/2006	CA2599419A1 Dipeptidyl peptidase-iv inhibitors
11/02/2006	CA2571710A1 Small molecule immunopotentiators and assays for their detection
11/02/2006	CA2505808A1 Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
11/01/2006	CN1856709A Method of predicting spot formation on the skin with the use of spot site-accelerating genes as indication and method of screening inhibitor for spot formation on the skin
11/01/2006	CN1856572A Use of RNAi inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
11/01/2006	CN1856499A New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
11/01/2006	CN1856498A Thienopyridine and furopyridine kinase inhibitors
11/01/2006	CN1856497A Ligands
11/01/2006	CN1856496A HIV-replikasjonshemmede purinderivater
11/01/2006	CN1856495A Imidazopyridine-derivatives as inducible NO-synthase inhibitors
11/01/2006	CN1856494A Imidazopyridine-derivatives as inducible NO-synthase inhibitors
11/01/2006	CN1856493A Aminopyridine-derivatives as inductible NO-synthase inhibitors
11/01/2006	CN1856492A Imidazo(4,5-B)pyridine-derivatives as inducible NO-synthase inhibitors
11/01/2006	CN1856491A Imidazopyridine-derivatives as inductible NO-synthase inhibitors
11/01/2006	CN1856490A Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
11/01/2006	CN1856488A Carbamoyl-type benzofuran derivatives
11/01/2006	CN1856487A Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
11/01/2006	CN1856486A Substituted lactams and their use as anti-cancer agents
11/01/2006	CN1856485A Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
11/01/2006	CN1856479A Gamma-secretase inhibitors
11/01/2006	CN1856478A Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
11/01/2006	CN1856477A 异喹啉钾通道抑制剂 Isoquinoline potassium channel inhibitors
11/01/2006	CN1856476A Isoquinolinone potassium channel inhibitors
11/01/2006	CN1856475A 异喹啉钾通道抑制剂 Isoquinoline potassium channel inhibitors
11/01/2006	CN1856474A Isoquinolinone potassium channel inhibitors
11/01/2006	CN1856473A Isoquinolinone potassium channel inhibitors
11/01/2006	CN1856472A Isoquinolinone potassium channel inhibitors

1 ... 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 4045 4046 4047 4048 ... 7860